Source:http://linkedlifedata.com/resource/pubmed/id/12480040
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2002-12-13
|
| pubmed:abstractText |
We examined the effect of cilostazol, a type III phosphodiesterase inhibitor, on pain-free and maximal walking distance and quality of life measures. The present study examined adverse effects in 2,702 patients with stable, moderate to severe claudication enrolled in 8 randomized, double-blind, placebo-controlled trials. Treatment duration ranged from 12 to 24 weeks. Cilostazol therapy increased maximal and pain-free walking distances by 50% and 67%, respectively. In subgroup analysis, cilostazol increased pain-free and maximal walking distance similarly in men and women, in older (>/=65 years) and younger patients, and in patients with and without diabetes. Quality-of-life assessments revealed enhanced scores for physical well-being. Cilostazol-treated patients reported a higher incidence of headache, bowel complaints, and palpitations than patients given placebos. Cilostazol decreased triglycerides by 15.8% and increased high-density lipoprotein cholesterol by 12.8%, but there were no deleterious effects on any hematologic or serum markers. We conclude that cilostazol significantly increases walking distance and quality-of-life measures in patients with claudication without major adverse effects.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Pentoxifylline,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/Vasodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/cilostazol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0002-9149
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
90
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1314-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12480040-Aged,
pubmed-meshheading:12480040-Cholesterol, HDL,
pubmed-meshheading:12480040-Clinical Trials, Phase III as Topic,
pubmed-meshheading:12480040-Double-Blind Method,
pubmed-meshheading:12480040-Exercise Test,
pubmed-meshheading:12480040-Female,
pubmed-meshheading:12480040-Humans,
pubmed-meshheading:12480040-Intermittent Claudication,
pubmed-meshheading:12480040-Male,
pubmed-meshheading:12480040-Multicenter Studies as Topic,
pubmed-meshheading:12480040-Pentoxifylline,
pubmed-meshheading:12480040-Phosphodiesterase Inhibitors,
pubmed-meshheading:12480040-Quality of Life,
pubmed-meshheading:12480040-Randomized Controlled Trials as Topic,
pubmed-meshheading:12480040-Tetrazoles,
pubmed-meshheading:12480040-Treatment Outcome,
pubmed-meshheading:12480040-Triglycerides,
pubmed-meshheading:12480040-Vasodilator Agents,
pubmed-meshheading:12480040-Walking
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
|
| pubmed:affiliation |
Hartford Hospital, Hartford, Connecticut 06102, USA. pthomps@harthosp.org
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|